Edition:
United States

Cellectis SA (ALCLS.PA)

ALCLS.PA on Paris Stock Exchange

24.01EUR
14 Dec 2017
Change (% chg)

-- (--)
Prev Close
€24.01
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
127,501
52-wk High
€30.00
52-wk Low
€15.64

Latest Key Developments (Source: Significant Developments)

Cellectis, Servier And Pfizer Present Preliminary Data From Two UCART19 Phase I Studies
Wednesday, 13 Dec 2017 01:56am EST 

Dec 13 (Reuters) - CELLECTIS ::SERVIER AND PFIZER PRESENT PRELIMINARY DATA FROM UCART19 PHASE I STUDIES IN ADULT AND PEDIATRIC PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA.STUDIES DEMONSTRATED SAFETY AND TOLERABILITY OF UCART19.STUDIES RESULTED IN 83-PCT COMPLETE REMISSION RATE ACROSS THE PATIENT POPULATION.IN 'CALM' TRIAL (UCART19 IN ADVANCED LYMPHOID MALIGNANCIES) FOR ADULTS, FIVE OUT OF SEVEN PATIENTS ACHIEVED MOLECULAR REMISSION AT DAY 28.'CALM' TRIAL: ONE GRADE 1 CUTANEOUS ACUTE GVHD OCCURED; NO SEVERE NEUROTOXICITY OBSERVED; CYTOKINE RELEASE SYNDROMES WERE MOSTLY MANAGEABLE.ONE PATIENT IN 'CALM' TRIAL DEVELOPED GRADE 4 CYTOKINE RELEASE SYNDROME AND NEUTROPENIC SEPSIS LEADING TO DEATH AT DAY 15.IN 'PALL' TRIAL (PEDIATRIC ACUTE LYMPHOBLASTIC LEUKEMIA) FOR CHILDREN, ALL FIVE PATIENTS ACHIEVED MOLECULAR REMISSION;.'PALL' TRIAL: ONE GRADE 1 CUTANEOUS ACUTE GVHD OCCURED; NO SEVERE NEUROTOXICITY OBSERVED.'PALL TRIAL': CYTOKINE RELEASE SYNDROMES WERE MOSTLY MANAGEABLE.  Full Article

Cellectis Appoints Stéphane Depil Senior VP Research & Development And Chief Medical Officer
Monday, 4 Dec 2017 04:31pm EST 

Dec 4 (Reuters) - CELLECTIS SA ::CELLECTIS APPOINTS IMMUNO-ONCOLOGY LEADER STÉPHANE DEPIL TO POSITION OF SENIOR VICE PRESIDENT RESEARCH & DEVELOPMENT AND CHIEF MEDICAL OFFICER.  Full Article

Cellectis says cash position at Sept. 30 of $304.1 million
Tuesday, 14 Nov 2017 03:39am EST 

Nov 14 (Reuters) - CELLECTIS SA ::ANNOUNCED ON MONDAY: CASH, CASH EQUIVALENTS AND CURRENT FINANCIAL ASSETS AT SEPT 30 STOOD AT $304.1 MLN VS $271.2 MLN AT JUNE 30 .Q3 TOTAL REVENUES AND OTHER INCOME $7.3 MLN VS $12.6 MLN YEAR AGO.Q3 FINANCIAL LOSS $3.4 MLN VS LOSS OF $1.2 MLN YEAR AGO .Q3 NET LOSS ATTRIBUTABLE TO SHAREHOLDERS $26.2 MLN VS LOSS OF $14.1 MLN YEAR AGO.EXPECTS ITS CASH, CASH EQUIVALENTS AND CURRENT FINANCIAL ASSETS WILL BE SUFFICIENT TO FUND ITS CURRENT OPERATIONS INTO 2020.  Full Article

Fda lifts clinical hold on cellectis phase 1 clinical trials with UCART123 in AML and BPDCN
Monday, 6 Nov 2017 07:01pm EST 

Nov 6 (Reuters) - Cellectis SA :FDA lifts clinical hold on cellectis phase 1 clinical trials with UCART123 in AML and BPDCN.Says ‍working with investigators and clinical sites to obtain IRB'S approval on revised protocols and resume patient enrollment​.Cellectis SA says ‍agreed with FDA to decrease of cohort dose level to 6.25x10(4) UCART123 cells/ in Phase 1 UCART123 protocols​.  Full Article

Cellectis says FDA places clinical hold of UCART123 studies following fatality
Monday, 4 Sep 2017 10:14pm EDT 

Sept 5 (Reuters) - CELLECTIS SA ::ANNOUNCED TODAY HAVING RECEIVED NOTICE FROM FDA THAT CLINICAL HOLD WAS PLACED ON BOTH UCART123 ONGOING PHASE 1 STUDIES IN ACUTE MYELOID LEUKEMIA (AML) AND IN BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM (BPDCN).CLINICAL HOLD WAS INITIATED AFTER CELLECTIS REPORTED ONE FATALITY IN BPDCN CLINICAL TRIAL (ABC STUDY).CELLECTIS IS WORKING CLOSELY WITH THE INVESTIGATORS AND THE FDA IN ORDER TO RESUME THE TRIALS WITH AN AMENDED PROTOCOL INCLUDING A LOWERED DOSING OF UCART123.  Full Article

Cellectis reports Q2 operating loss of 18.0 million euros
Thursday, 3 Aug 2017 01:48am EDT 

Aug 3 (Reuters) - CELLECTIS SA ::SAID ON WEDNESDAY FIRST AML PATIENT TREATED WITH UCART123 ENROLLMENT ONGOING.IND CLEARANCE GRANTED BY THE FDA TO SERVIER AND PFIZER RELATED TO PHASE I CLINICAL TRIALS OF UCART19 IN ALL PATIENTS.CLOSING OF THE CALYXT’S NASDAQ IPO WITH $64.4 MILLION IN GROSS PROCEEDS TO CALYXT ON JULY 25, 2017.STRONG CASH POSITION OF $272 MILLION (€238 MILLION) AS OF JUNE 30, 2017.AT JUNE 30, 2017, CELLECTIS HAD € 237.6 MILLION IN TOTAL CASH, CASH EQUIVALENTS AND CURRENT FINANCIAL ASSETS COMPARED TO € 258.5 MILLION AT MARCH 31, 2017.Q2 TOTAL REVENUES AND OTHER INCOME EUR 8.2 MLN VS 18.1 MLN YR AGO.Q2 OPERATING LOSS EUR 18.0 MLN VS LOSS OF EUR 10.0 MLN YR AGO.Q2 NET LOSS EUR 24.1 MLN VS LOSS OF EUR 6.3 MLN YR AGO.FOR THE QUARTERS ENDED AT JUNE 30, 2016 AND 2017, RESEARCH AND DEVELOPMENT EXPENSES DECREASED BY €2.6 MILLION FROM €19.5 MILLION IN 2016 TO €16.9 MILLION IN 2017.  Full Article

Cellectis says Calyxt receives about 64.4 million dollars in IPO
Wednesday, 26 Jul 2017 01:40am EDT 

July 26 (Reuters) - CELLECTIS ::TOGETHER WITH CALYXT ANNOUNCED ON TUESDAY FULL EXERCISE OF OVER-ALLOTMENT OPTION AND CLOSING OF CALYXT'S INITIAL PUBLIC OFFERING.CALYXT'S IPO AMOUNTS TO 8,050,000 SHARES OF ITS COMMON STOCK AT PRICE OF $8.00 PER SHARE.CALYXT RECEIVED APPROXIMATELY $64.4 MILLION IN PROCEEDS FROM THE OFFERING.  Full Article

Cellectis is granted patent for CRISPR use in T-cells
Tuesday, 25 Jul 2017 01:55am EDT 

July 24 (Reuters) - CELLECTIS SA ::ANNOUNCED ON MONDAY ABOUT THE GRANT BY THE EUROPEAN PATENT OFFICE OF PATENT NO. EP3004337 FOR THE INVENTION OF USING RNA-GUIDED ENDONUCLEASES, SUCH AS CAS9 OR CPF1 FOR THE GENETIC ENGINEERING OF T-CELLS.THE PATENT WILL BE ISSUED ON AUGUST 2, 2017 .  Full Article

Cellectis announces subsidiary's Calyxt’s IPO
Thursday, 20 Jul 2017 01:42am EDT 

July 20 (Reuters) - CELLECTIS SA ::ANNOUNCES SUBSIDIARY'S CALYXT’S INITIAL PUBLIC OFFERING OF 7,000,000 SHARES.THE INITIAL PUBLIC OFFERING PRICE OF $8.00 PER SHARE, DECREASE FROM THE PREVIOUSLY DISCLOSED ESTIMATED PRICE RANGE OF $15.00 TO $18.00 PER SHARE.OFFERING IS EXPECTED TO CLOSE ON OR ABOUT JULY 25, 2017.  Full Article

Cellectis says Calyxt prices $56 mln initial public offering
Wednesday, 19 Jul 2017 06:33pm EDT 

July 19 (Reuters) - Cellectis SA - :Cellectis: Calyxt announces pricing of $56.0 million initial public offering.Pricing of Calyxt's initial public offering of 7 million shares of common stock at IPO price of $8.00 per share.  Full Article

BRIEF-Cellectis, Servier And Pfizer Present Preliminary Data From Two UCART19 Phase I Studies

* SERVIER AND PFIZER PRESENT PRELIMINARY DATA FROM UCART19 PHASE I STUDIES IN ADULT AND PEDIATRIC PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA